Submissions for variant NM_002880.4(RAF1):c.94A>G (p.Ile32Val)

gnomAD frequency: 0.00013  dbSNP: rs372738063

Total submissions: 9

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
ClinGen RASopathy Variant Curation Expert Panel	RCV000788000	SCV000927032	benign	Noonan syndrome and Noonan-related syndrome	2019-06-27	reviewed by expert panel	curation	The c.94A>G (p.Ile32Val) variant in the RAF1 gene has been identified in patients who underwent testing for a RASopathy, however it has also been identified in multiple adults who did not have clinical features of a RASopathy (BS2, BP5; Invitae, EGL Diagnostics, GeneDx internal data; GTR Lab ID: 500031, 500060; SCV000287747.4, SCV000227277.5, SCV000209002.14). The filtering allele frequency of the p.Ile32Val variant is 0.017% for European (non-Finnish) genomes in the gnomAD database (8/31404 with 95% CI) which is a high enough frequency to be considered strong evidence that the variant is benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BS1). Computational prediction tools and conservation analysis suggest that the p.Ile32Val variant does not impact the protein (BP4). In summary, this variant meets criteria to be classified as benign. RASopathy-specific ACMG/AMP criteria applied (PMID:29493581): BS2, BP5, BS1, BP4.
GeneDx	RCV000680302	SCV000209002	likely benign	not provided	2018-08-09	criteria provided, single submitter	clinical testing	This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Eurofins Ntd Llc (ga)	RCV000159060	SCV000227277	likely benign	not specified	2015-08-21	criteria provided, single submitter	clinical testing
Labcorp Genetics (formerly Invitae), Labcorp	RCV000229182	SCV000287747	benign	RASopathy	2024-01-18	criteria provided, single submitter	clinical testing
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine	RCV000159060	SCV000966503	likely benign	not specified	2018-03-19	criteria provided, single submitter	clinical testing	p.Ile32Val in exon2 of RAF1: This variant has been identified in 0.02% (22/12673 0) of European chromosomes and 0.03% (6/24036) of African chromosomes by the Gen ome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs3727 38063) and was found in a case with an alternate explanation for disease. In add ition, computational prediction tools do not suggest a high likelihood of impact to the protein. ACMG/AMP Criteria applied: BS1; BP5; BP4.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV000159060	SCV001339226	likely benign	not specified	2024-02-05	criteria provided, single submitter	clinical testing	Variant summary: RAF1 c.94A>G (p.Ile32Val) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00027 in 1614104 control chromosomes in the gnomAD database, including 1 homozygotes. The observed variant frequency is approximately 11 fold of the estimated maximal expected allele frequency for a pathogenic variant in RAF1 causing Noonan Syndrome And Related Conditions phenotype (2.5e-05), strongly suggesting that the variant is benign. c.94A>G has been reported in the literature in at-least one individual affected with T-cell ALL (example, Zhang_2016). This report however, does not provide unequivocal conclusions about association of the variant with Noonan Syndrome and Related Conditions. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication has been ascertained in the context of this evaluation (PMID: 26580448). ClinVar contains an entry for this variant (Variation ID: 40584). Based on the evidence outlined above, the variant was classified as likely benign.
Ambry Genetics	RCV002371808	SCV002685975	uncertain significance	Cardiovascular phenotype	2024-05-19	criteria provided, single submitter	clinical testing	The p.I32V variant (also known as c.94A>G), located in coding exon 1 of the RAF1 gene, results from an A to G substitution at nucleotide position 94. The isoleucine at codon 32 is replaced by valine, an amino acid with highly similar properties. This alteration has been reported in an oculoauriculofrontonasal syndrome (OAFNS) cohort (Lehalle D et al. Am J Med Genet A, 2018 12;176:2740-2750). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
CeGaT Center for Human Genetics Tuebingen	RCV000680302	SCV004701047	likely benign	not provided	2022-09-01	criteria provided, single submitter	clinical testing	RAF1: BP4
PreventionGenetics, part of Exact Sciences	RCV004737168	SCV005361308	benign	RAF1-related disorder	2024-07-09	no assertion criteria provided	clinical testing	This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications).